Kohei Takano
Scientist Daiichi Sankyo
Seminars
Wednesday 14th October 2026
Highlighting Preclinical Development of DS-3939a, a DXd-ADC Targeting TA-MUC1
2:00 pm
- Overviewing the DXd-ADC technology platform and pipeline
- Exploring target biology and rationale for targeting TA-MUC1 with an ADC in solid tumors
- Highlighting the preclinical pharmacology profile of DS-3939a, a TA-MUC1 directed DXd-ADC
